Chronic Dry Eye Disease

“I call on my colleagues not to become virtual doctors, but remain actual doctors using virtual technology.” – Paula Muto, MD, FACS

In patients with dry eye disease caused by ocular graft-vs.-host disease, Marta Ponce Contreras, MD, and colleagues found cryopreserved amniotic membrane treatment improved ocular signs and symptoms in patients whose disease was refractory to conventional therapy.

A phase 1 clinical trial of Ocular Therapeutix’s dry eye treatment OTX-CSI is underway, with the first patient being dosed, the company announced.

Kala Pharmaceuticals resubmitted a new drug application to the FDA for Eysuvis, a candidate for the short-term treatment of dry eye disease signs and symptoms, according to a company press release.

“Screen time won the great screen time war.” – Craig Garthwaite

RegeneRx Biopharmaceuticals, in association with its Korean partner GtreeBNT, announced a status update in response to the COVID-19 pandemic on a phase 3 clinical trial of RGN-295 for the treatment of dry eye disease, according to a press release.

The American Society of Cataract and Refractive Surgery Cornea Clinical Committee has provided us another excellent guideline for the diagnosis and management of dry eye disease.

Enrollment has been completed in a pivotal phase 3 trial of OC-01 nasal spray for the treatment of signs and symptoms of dry eye disease, Oyster Point Pharma announced in a press release.

SAN FRANCISCO —Noninvasive internasal neurostimulation with TrueTear increased tear volume as well as reduced ocular dryness and pain intensity in patients with dry eye symptoms, according to a presentation at the American Academy of Ophthalmology annual meeting.

Optometry is undergoing a tectonic shift, with online contact lens and eyeglass sales, telemedicine and equity capital group acquisitions all pointing to significant changes ahead. To prepare, we must identify unmet needs and expand our practices to meet them.